Pacific Edge reviews US pricing for new Cxbladder test, trading halted

Pacific Edge reviews US pricing for new Cxbladder test, trading halted
Pacific Edge says Cxbladder Triage Plus delivers “significant performance improvements” compared to its existing tests. (Image: Pacific Edge)
Rebecca Howard
Pacific Edge has been placed on a trade halt while it reviews draft gapfill or reimbursement rates for its new Cxbladder Triage Plus test from the US Centres for Medicare and Medicaid Services.“[It said it's] reviewing the prices and the associated documentation and needs time to assess the implications of them, consult with its advisers and industry partners, and prepare an announcement that provides context to investors.”Gapfill prices are proposed reimbursement rates for new or unpriced clinical diagnostic laboratory tests.Th...

More Markets

NZX 50 down 0.4% as Israel-Iran conflict heats up
Markets Market Close

NZX 50 down 0.4% as Israel-Iran conflict heats up

Infratil rose nearly 4% during an announcement-light day on the bourse.

Gentrack now one of NZ's most valuable listed companies
Markets

Gentrack now one of NZ's most valuable listed companies

Utilities software provider keeps winning customers and moving up the NZX.

THL buyout offer lifts NZX 50
Markets Market Close

THL buyout offer lifts NZX 50

Tourism Holdings helped the NZX 50 rise 1.09%.

Gregor Thompson 16 Jun 2025
THL exec enlists private equity for takeover bid
Markets

THL exec enlists private equity for takeover bid

In tandem with the offer, the consortium has amassed a 19.99% stake in THL.

Gregor Thompson 16 Jun 2025
OSZAR »